The Evaluation of Treatment Outcome of Multidrug-resistant Tuberculosis (RR/MDR-TB) Patients for Treatment with All New oral Shorter Regimen in Health Region 7

Abstract

        The present study aimed to evaluate the multidrug-resistant tuberculosis(RR/MDR-TB) treatment outcome and side effects with all new oral shorter regimen in health region 7. This cross-section study included  22 multidrug-resistant Tuberculosis (RR/MDR-TB) patients  who were diagnosed and registered for treatment of drug-resistant tuberculosis in 6 public hospitals and carried out between March 2020 and September 2021. The instrument of gathering data used records from and in-depth interview. Data were analyzed using descriptive statistics and content analysis.  

          The results revealed that the majority of the patients was men (59.09%) and the mean age was 47.6 years (S.D. = 15.75). Among patients successfully treatment, The treatment duration was 11 months (50.0%), and 9 months (45.46%) mostly, It was a few as 18 months (4.54%). Comorbidities were more than half (54.5%) of patients. There were mostly(81.81%) no history  of TB household contacts and directly observed treatment (95.5%). In the classification of patients, There were RR/MDR-TB (95.45%) mostly and rifampicin resistance-TB (4.55 %) respectively. The mean weight was 53.04 kg. (S.D. = 11.14),  The most common shorter regimens were used 6Bdq-Mfx-Pto-Cfz-Z—H (high-dose)-E/5Mfx-Cfz_Z_E, 4Bdq-Mfx-Pto-Cfz-Z—H(high-dose)-E/5Mfx-Cfz_Z_E  and a extension duration  with 18 months (50.00%, 45.46% and 4.54 %) respectively.  With the acid fast stain diagnosed method and culture diagnosed method, The sputum of  patients were changed  from positive to negative within completely 1 months  as 81.81% and 72.72%.  All patient were completely in 9 months and 11 months with 2 method.  The success rate of treatment  was  95.45%  and 4.55 %  for extend treatment (18 months)  due to any symptom, such as hepatitis, weakness, nausea and vomiting. The most adverse reactions were joint pain (31.82%), nausea, vomiting and itchy skin rash (27.28%) and dizziness/ear off (18.18%)

          All patients who has been completely treated, should be fallowed  up and re-examed every 6 or 12 months. The treatment of drug-resistant tuberculosis requires a long maintenance phase. Therefore, the consultation system for patients to understand the present disease and medications is the most important as well as the increased cure rate.